Harnessing neoantigen-specific T cells for precision immunotherapy in hematologic malignancies

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Antigen-specific T-cell immunotherapies are revolutionizing hematologic malignancy treatment.
• Neoantigen-specific therapies leverage endogenous T-cell receptors (TCRs) for HLA-restricted tumor peptide recognition, distinct from HLA-independent chimeric antigen receptor (CAR) T cells.
• Neoantigen strategies provide enhanced tumor selectivity and reduced toxicity compared to tumor-associated antigen (TAA) approaches.

Purpose of the Study:

• To review recent advances in neoantigen-specific strategies for blood cancers.
• To highlight translational insights for prioritizing immunogenic neoantigens.
• To identify barriers limiting therapeutic efficacy and guide future development.

Main Methods:

• Synthesis of pre-clinical and clinical data on neoantigen discovery and validation.
• Analysis of advancements in immunogenomics, immunopeptidomics, and TCR characterization.
• Review of early-phase clinical trial data for safety, feasibility, and efficacy.

Main Results:

• Neoantigen-specific strategies demonstrate safety and feasibility in early clinical trials for hematologic malignancies.
• Advances in sequencing and validation technologies accelerate neoantigen and TCR identification.
• Ongoing studies are evaluating the immunogenicity, clinical efficacy, and durability of these therapies.

Conclusions:

• Neoantigen-specific immunotherapies hold significant promise for treating blood cancers with improved precision.
• Addressing biological and technological barriers is crucial for maximizing therapeutic potential.
• Further research and clinical trials are essential to optimize these innovative treatments.